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Background: Severe acute respiratory syndrome (SARS) is an emerging infectious disease, and indeed, the SARS
epidemic in Taiwan from March to July 2003 had a great impact. This study depicts the clinical characteristics and
short-term outcomes of patients with SARS treated at Taipei Veterans General Hospital; potential predictive factors
for acute respiratory distress syndrome (ARDS) are also analyzed.
Methods: This study retrospectively analyzed data for 67 SARS patients, who were grouped according to whether
or not ARDS developed during the clinical course of SARS.
Results: There were 32 males (mean age, 50.3 years; range, 20–75 years) and 35 females (mean age, 51.1 years;
range, 23–86 years). Twenty-five patients (37.3%) were health care workers. At admission, 50 patients (74.6%)
had abnormal chest radiographs, and all patients developed pulmonary infiltrates during the following week. During
hospitalization, lymphopenia was found in 57 patients (85.1%); and elevated levels of lactate dehydrogenase (LDH;
n = 55; 83.3%), C-reactive protein (n = 55; 83.3%), aminotransferases (n = 44; 65.7%), and creatine kinase
(n = 14; 20.9%) were also noted. ARDS developed in 33 patients (49.3%), who were generally older than the patients
in whom ARDS did not develop, male, non-health care workers, and who generally had dyspnea at the time of diagnosis,
and a history of diabetes mellitus, hypertension or cerebrovascular accident. Patients with, versus those without,
ARDS also tended to present with more severe lymphopenia and leukocytosis, and with higher levels of LDH and
aspartate aminotransferase. The overall mortality rate was 31.3% (21/67), whereas the rate for patients who developed
ARDS was 63.6% (21/33). Multivariate analyses showed that age greater than 65 years (odds ratio, OR, 10.6;
95% confidence interval, CI, 2.1–54.1), pre-existing diabetes mellitus (OR, 13.7; 95% CI, 1.3–146.9), and elevated
levels of LDH (OR, 8.4; 95% CI, 1.9–36.9) at admission, were independent predictors of ARDS.
Conclusion: The clinical manifestations of SARS showed high variability, and were related to the underlying health
status of individual patients. Importantly, the development of ARDS was associated with significant mortality, despite
aggressive therapy. [J Chin Med Assoc 2005;68(1):4–10]
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Introduction
Severe acute respiratory syndrome (SARS) is an
infectious pulmonary disease that appears to have
originated in southern China in the fall of 2002. The
disease then spread to other parts of Asia, Europe and
North America, with more than 8,000 cases now
reported worldwide.1–5
The first two SARS cases in Taiwan were diagnosed
in a couple on March 14, 2003;6 the man had traveled
to Guangdong Province and Hong Kong in February
2003. The couple was treated successfully in an intensive
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care unit (ICU) at medical center A. Subsequently,
most SARS patients were treated at that medical
center, until two clusters of cases were noted in late
April, 2003, in Taipei. The origin of the outbreak was
a laundry worker, aged 42 years, with diabetes mellitus,
who was employed at hospital B.7 As the index patient
had been symptomatic for 6 days before SARS was
diagnosed, the number of potentially exposed persons
was estimated to be 10,000 patients and visitors, and
930 staff. Within less than 2 weeks, another outbreak
of SARS clusters occurred in hospital C, which is near
hospital B. Taipei Veterans General Hospital under-
took the care of critically ill SARS patients, who were
mainly transferred from hospital B and hospital C.
The cause of SARS is a novel coronavirus.8–11
Natural clinical histories have ranged from febrile
respiratory symptoms, without hypoxemia, to
respiratory distress requiring intubation and,
occasionally, resulting in death.3–4 Worldwide, the
substantial mortality associated with SARS has varied
markedly from 15–27%.5 This paper provides a
retrospective review of predictive factors for acute
respiratory distress syndrome (ARDS) in patients with
SARS treated at Taipei Veterans General Hospital.
Methods
Clinical diagnostic criteria
The following criteria were used to evaluate the
probability of SARS:
1. A history of close contact with a SARS patient, or
evidence of traveling to SARS-endemic areas within
10 days before symptom onset.
2. Acute onset of fever > 38$C.
3. Respiratory symptoms, including cough or dyspnea.
4. Chest radiograph showing patchy or spotty pul-
monary infiltrates.
5. ARDS without an identifiable cause.
6. Evidence of the transmission of pneumonia.
Patients fulfilling criteria 1+2+3 were defined as
suspected cases, while those meeting criteria 1+2+3+4,
2+3+5, or 2+3+4+6 were defined as probable cases. A
diagnosis of SARS was not made if an alternative
diagnosis could fully explain the illness. Reverse
transcriptase-polymerase chain reaction (RT-PCR),
or antibodies for SARS-coronavirus (SARS-CoV), were
used to confirm the diagnosis, but were not part of the
diagnostic criteria.
Study patients
This study included all patients with SARS admitted to
Taipei Veterans General Hospital between March 20
and July 5, 2003, even though 14 cases in our cohort
were reported previously by Chiang et al.12 Thirty-
three patients were referred due to evidence of SARS
noted at another hospital. These patients were cate-
gorized according to the most severe clinical condi-
tion, i.e. non-ARDS or ARDS, with ARDS defined
according to the American-European consensus con-
ference:13
1. Non-ARDS: patients with a ratio of partial arterial
oxygen pressure (PaO2)/fractional inspired oxygen
(FIO2) > 200 mmHg, and who did not develop
ARDS during their stay in the ward.
2. ARDS: patients with PaO2/FIO2 ) 200 mmHg,
and with bilateral lung infiltrates at admission or
during their stay in the ward.
Treatment
All patients were isolated for treatment, which included
antibiotics to prevent secondary bacterial infection.
The choice of antibiotics was based on empirical
knowledge of the common atypical pathogens en-
countered in the community. Other antibiotics were
administered to patients with established bacterial
infection according to the results of drug-sensitivity
testing after bacterial culture. The administration of
ribavirin, intravenous immunoglobulin or cortico-
steroids was determined by physicians. Patients were
intubated when respiratory failure developed, i.e.
PaO2 < 90% during the administration of 100% sup-
plemental oxygen with or without a respiratory rate of
more than 35 breaths per minute.
Study design
A clinical database was constructed to document patient
demographics, including the following: date of onset
of initial symptoms; initial abnormal radiographic
findings; date of admission to the hospital; tracheal
intubation with mechanical ventilation; other comor-
bid conditions; and treatments for, and short-term
outcomes of, the acute illness. The main parameters
monitored at, and every 2–3 days after, hospital
admission comprised complete blood count (CBC),
aspartate aminotransferase (AST), alanine amino-
transferase (ALT), blood urea nitrogen, creatinine,
creatine kinase (CK), lactate dehydrogenase (LDH),
C-reactive protein (CRP), and blood gases. Chest
films were taken daily during the early hospital stay,
and every 2–5 days during convalescence. RT-PCR for
SARS-CoV was performed routinely on nasopharyn-
geal swabs on days 1 and 7 of hospitalization. Assays
for anti-SARS-CoV antibodies were performed on day
21 of hospitalization, and 2 weeks after hospital
discharge.
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Statistical analysis
We compared differences in epidemiologic, clinical,
and laboratory measures between patients who
developed ARDS and those who did not. Square-root
transformation was performed, for CBCs and bio-
chemical parameters, for the normality of data. The
Kolmogorov-Smirnov test was used to check normality.
The Student’s t test was adapted to normal-distribution
data. For continuous variables not fitted to a normal
distribution, median and interquartile ranges (IQRs)
were calculated as summaries of distribution, and a
Wilcoxon rank-sum test was adapted for comparison.
A Chi-squared test was used to compare the category
variables. For calculating the odds ratio of ARDS in
the logistic regression analysis, each variable was
dichotomized using a “normal-limits” value as cut-
off (except for CRP [cut-off, 5 mg/L] and age [65
years]). To dichotomize the variable “comorbidities”,
the study group was divided into patients with (value
of 1) or without underlying disease (value of 0). A
p value of less than 0.05 was considered statistically
significant. All analyses were carried out using Statisti-
cal Package for the Social Sciences version 11.0 (SPSS
Inc, Chicago, IL, USA).
Results
Demographics and clinical information
A total of 67 patients with SARS were admitted to our
hospital between March 20 and July 5, 2003, which
represented 10% (67 of 668) of all documented, prob-
able SARS cases in Taiwan. The patients comprised 32
men and 35 women; mean age ( standard deviation
(SD) was 51.0 ( 21.9 years (range, 23–86 years)
(Table 1). Twenty-five patients (37.3%) were medical
professionals and the others had various occupations.
Thirty-three (49.3%) patients required mechanical
ventilatory support.
Patients without ARDS were significantly younger
than patients with ARDS (39.1 ( 16.5 years vs 63.4 (
20.0 years). All patients received nasopharyngeal-
swab RT-PCR tests routinely on days 1 and 7 of
hospitalization, and only 22 patients (32.8%) had
positive findings. Thirty-three patients had assays for
anti-SARS-CoV antibodies on day 21 of hospitalization;
28 of them (84.8%) had positive findings. The most
common initial clinical symptoms were fever (95.5% of
patients), cough (65.7%) and dyspnea (49.3%); watery
diarrhea was noted in less than 20% of patients. Forty-
two patients (62.7%) had other comorbid conditions,
which principally included diabetes mellitus (n = 16),
viral hepatitis (n = 12), hypertension (n = 13), and
cerebrovascular accident (CVA; n = 8). Levofloxacin
was used in a total of 49 patients (73.1%), whereas
other antibiotics were used significantly more frequently
in patients with ARDS rather than in those without
(26 vs 17; p = 0.021). The administration of ribavirin,
intravenous immunoglobulin or corticosteroids did
not differ significantly between patients with ARDS
and those without, although pulse corticosteroid
therapy (methylprednisolone 500 mg intravenously
every 12 hours for 2–3 days) was given to four  patients
with ARDS versus none of the non-ARDS patients
(p = 0.053). The mean length of hospital stay was
significantly shorter for patients without ARDS than
for survivors of ARDS (19.8 days vs 39.3 days; p <
0.001) (Table 1).
The overall mortality rate was 31.3% (21 of 67
patients), whereas the mortality rate for patients who
underwent mechanical ventilation was 63.6% (21 of
33).
Laboratory data
Laboratory indices during hospitalization are sum-
marized in Table 2. Sixteen patients (23.9%) had a
leukocyte count < 3,500/mm3, 57 (85.1%) had a lym-
phocyte count < 1,000/mm3, and 15 (22.4%) had a
platelet count < 100,000/mm3. CK levels increased to
> 200 U/L in 14 of 67 patients (20.9%) and, among
a group of 66 evaluable patients, elevated levels of the
following parameters were noted: AST > 45 U/L in 42
patients (63.6%); LDH > 213 U/L in 55 (83.3%);
and a CRP increase of up to 1 mg/dL in 55 patients
(83.3%), and of up to 5 mg/L in 41 (62.1%).
Radiographic findings
Chest radiographs revealed changes relating to
pneumonia, although 17 patients (25.4%) did not
have pulmonary infiltrates at initial radiograph. Com-
bined central and peripheral lesions were evident in
most patients, and most had rapid progression from
a single localized lesion. The most common locations
were the bilateral lower lung regions (Table 3). In the
17 patients with an initial normal radiograph, and who
subsequently developed consolidation, the average
time from fever onset to an abnormal radiograph was
4.6 ( 6.8 days (range, 1–13 days).
Predictive factors for ARDS
We used a logistic multiple regression model to uncover
risk factors for the development of ARDS. This model
included LDH, CRP, age more than 65 years, diabetes
mellitus, hypertension, previous CVA, and male gender,
from univariate logistic regression analyses. Odds ratios
for ARDS development in the 67 patients with SARS
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Table 1. Characteristics of SARS patients at Taipei Veterans General Hospital
Non-ARDS (n = 34) ARDS (n = 33) Total (n = 67)      p*dd
Age (yr), mean (range) 39.1 (23–76)11d 63.4 (27–86)ss11 51.0 (23–86)  11 < 0.001
Male gender, n (%) 12 (35.3)11d 20 (60.6)ss11 32 (47.8)  11 0.038
Health care workers, n (%) 17 (50.0)11d 8 (24.2)s11 25 (37.3)  11 0.029
Positive RT-PCR for SARS, n (%) 6 (17.6)11 16 (48.5)ss11 22 (32.8)  11 0.010
Positive for anti-SARS-CoV antibodies†, n (%) 17/17 (100)ssss1111/16 (68.8)ssddd  28/33 (84.8)ssddd 0.018
Symptoms, n (%)
Fever 34 (100)11ff 30 (90.9)ss11 64 (95.5)  11 0.114
Cough 21 (61.8)1d1 23 (69.7)ss11 44 (65.7)  11 0.494
Dry 17 (50.0)1d1 18 (54.5)ss11 35 (52.2)  11 0.710
Productive 4 (11.8)11 5 (15.2)ss1 9 (13.4)  1 0.734
Dyspnea 9 (26.5)11 24 (72.7)ss11 33 (49.3)  11 < 0.001
Diarrhea 7 (20.6)11 5 (15.2)ss1 12 (17.9)  11 0.562
Malaise 6 (17.6)11 3 (9.1)ss11 9 (13.4)  1 0.476
Myalgia/arthralgia 7 (20.6)11 2 (6.1)ss11 9 (13.4)  1 0.150
Headache 2 (5.9)111 4 (12.1)ss1 6 (9.0)  11 0.427
Comorbidities, n (%)
Diabetes mellitus 1 (2.9)111 15 (45.5)ss11 16 (23.9)  11 < 0.001
HBV carrier 9 (26.5)11 3 (9.1)ss11 12 (17.9)  11 0.109
Hypertension 3 (8.8)111 10 (30.3)ss11 13 (19.4)  11 0.035
CVA 1 (2.9)111 7 (21.2)ss1 8 (11.9)  1 0.027
HCV infection 2 (5.9)111 3 (9.1)ss11 5 (7.5) 1 1 0.673
Old pulmonary TB 3 (8.8)111 2 (6.1)ss11 5 (7.5) 1 1 0.667
COPD or asthma 1 (2.9)111 3 (9.1)ss11 4 (6.0) 1 1 0.356
Cardiac disease 3 (8.8)111 4 (12.1)s11 7 (10.4)  1 0.709
Thyroid disease 1 (2.9)111 1 (3.0)ss11 2 (3.0) 1 1 0.983
Treatment, n (%)
Levofloxacin 29 (85.3)111 20 (60.6)ss11 49 (73.1) 1 1 0.029
Other antibiotics‡ 17 (50.0)111 26 (78.8)ss11 43 (64.2) 1 1 0.021
Ribavirin 16 (47.1)111 19 (57.6)ss11 35 (52.2) 1 1 0.466
IVIG 18 (52.9)111 19 (57.6)ss11 37 (55.2) 1 1 0.807
Non-pulse corticosteroid 19 (55.9)111 21 (63.6)ss11 40 (59.7) 1 1 0.621
Pulse corticosteroid 0 (0)1d 11 4 (12.1)1 1 4 (6.0) 1 1 0.053
Mean length of hospital stay, d (IQR) 19.8 (11.0–24.3) 39.3 (29.0–50.0)§ 24.9 (14.8–33.3)|| < 0.001
*ARDS vs non-ARDS; †33 patients received assays for anti-SARS-CoV antibodies on day 21 of hospitalization and 27 patients received enzyme-
linked immunosorbent assay for IgM and IgG SARS-CoV antibodies 2 weeks after discharge; ‡azithromycin, ampicillin/sulbactam, clindamycin,
cefuroxime, ceftriaxone, ceftazidime, cefepime, cefpirome, imipenem, meropenem, or teicoplanin; §length of hospital stay for survivors of ARDS;
||length of hospital stay for all survivors.
SARS = severe acute respiratory syndrome; ARDS = acute respiratory distress syndrome; RT-PCR = reverse transcriptase-polymerase chain reaction;
SARS-CoV = SARS-coronavirus; HBV = hepatitis B virus; CVA = cerebrovascular accident; HCV = hepatitis C virus; TB = tuberculosis; COPD = chronic
obstructive pulmonary disease; IVIG = intravenous immunoglobulin; IQR = interquartile range.
Table 2. Laboratory findings during the hospital course of SARS*
Non-ARDS, median (IQR) ARDS, median (IQR) <p
Lowest leukocyte count (per mm3) 4,050 (3,425–5,425) 6,300 (4,125–8,600) < 0.012
Lowest lymphocyte count (per mm3) 579 (448–983) 359 (372–766) 1 < 0.003
Lowest platelet count = 103 (per mm3) 152 (120–185) 131 (85–170)  1 < 0.068
Highest ALT (IU/L) 54 (29–119) 66 (33–120) 1 < 0.818
Highest AST (IU/L) 41 (30–88) 92 (56–138) 1 < 0.004
Highest creatine kinase (IU/L) 54 (23–86) 138 (56–455)  1 < 0.001
Highest LDH (IU/L) 257 (200–392) 517 (363–758) 1 < 0.001
Highest CRP (mg/dL) 4.3 (0.7–8.9) 12.7 (10.0–23.6)1 < 0.001
*Square-root transformation was performed for the normality of data.
SARS = severe acute respiratory syndrome; ARDS = acute respiratory distress syndrome; IQR = interquartile range; ALT = alanine aminotransferase;
AST = aspartate aminotransferase; LDH = lactate dehydrogenase; CRP = C-reactive protein.
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were 13.71 (95% confidence interval, CI, 1.28–
146.86) for patients with concurrent diabetes mellitus,
10.61 (95% CI, 2.08–54.14) for patients older than
65 years, and 8.43 (95% CI, 1.93–36.92) for patients
with elevated LDH (Table 4).
Discussion
Taiwan has had the third largest number of SARS
cases, after Hong Kong and China. To date, however,
no large, formal analysis of the data from Taiwan can
Table 3. Radiographic patterns at admission in 67 SARS patients
Non-ARDS (n = 34) ARDS (n = 33) Total, n (%)
Pattern of involvement
Central 10 11 1 (1.5)
Peripheral 13 19 22 (32.8)
Central and peripheral 18 19 27 (40.3)
Number of lesions
Unifocal 17 11 28 (41.8)
Multifocal, unilateral 13 17 10 (14.9)
Multifocal, bilateral 12 10 12 (17.9)
Number of involved zones
1 17 13 30 (44.8)
2 13 17 10 (14.9)
> 2 12 18 10 (14.9)
Lung zone*
Right upper 13 16 19 (13.4)
Right middle 14 12 16 (23.9)
Right lower 11 14 25 (37.3)
Left upper 10 13 3 (4.5)
Left middle 15 19 14 (20.9)
Left lower 17 16 23 (34.3)
Normal radiography 13 14 17 (25.4)
*Zone height was defined as one-third of the craniocaudal extent of the lungs.
SARS = severe acute respiratory syndrome; ARDS = acute respiratory distress syndrome.
Table 4. Predictors of ARDS in patients with SARS
Odds ratio (95% CI) p
Univariate analysis
Age > 65 yr 11.53 (3.28–40.48)1 < 0.001
Male gender 2.82 (1.05–7.60)1 0.04
Leukocyte count > 10,000/mm3 3.77 (1.16–12.25) 0.027
Lymphocyte count < 1,000/mm3 2.47 (0.87–7.02)1 0.09
Platelet count < 105/mm3 3.29 (0.33–33.35) 0.313
LDH > 213 IU/L 9.41 (3.01–29.41) < 0.001
ALT > 40 IU/L 1.20 (0.13–3.37)1 0.73
AST > 45 IU/L 5.24 (1.78–15.42) 0.003
Creatine kinase > 200 IU/L 5.89 (0.65–53.45) 0.115
Diabetes mellitus 31.04 (3.79–254.19) 0.001
HBV carrier 0.37 (0.07–2.08)1 0.262
Hypertension 4.49 (1.11–18.19) 0.035
Cerebrovascular accident 8.88 (1.03–76.69) 0.047
Multivariate analysis
Diabetes mellitus 13.71 (1.28–146.86) 0.030
Age > 65 yr 10.61 (2.08–54.14)1 0.005
LDH > 213 IU/L 8.43 (1.93–36.92) 0.005
ARDS = acute respiratory distress syndrome; SARS = severe acute respiratory syndrome ; CI = confidence interval; LDH = lactate dehydrogenase;
ALT = alanine aminotransferase; AST = aspartate aminotransferase; HBV = hepatitis B virus.
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be found in the English literature. In April 2003,
7 health care workers, including 2 physicians and
3 nurses, died from SARS in Taiwan; most of these
workers had worn surgical masks. Initial reports
showed that SARS had a high degree of respiratory
infectiousness and could possibly be transmitted
through airborne infection. Faced with an unknown
disease, we experienced much anxiety. Further, our
ICU had no negative-pressure design, and to protect
staff and patients, treatment was done in negative-
pressure isolation rooms with an antechamber; these
rooms were usually used for isolation of patients with
tuberculosis or acquired immune deficiency syndrome.
The transfer of patients from wards for examination
required an absolute indication. Bronchoscopy was
not recommended for patients with a typical clinical
picture and clear epidemiologic link. Anesthesiologists
stood by all day to perform intubations for SARS
patients. The isolation rooms were guarded by security
personnel, and infection control was guided by a team
of specialists.
Since our hospital was responsible for the man-
agement of critical cases in northern Taiwan, the
outcomes shown were more severe than in other
medical settings. Initial clinical presentations and la-
boratory features were similar to those in other series.
Symptoms of acute respiratory distress developed in
about half of the patients (33/67; 49.3%); 21 of these
patients (63.6%) died and the other 12 were discharged
from hospital. The risk factors for ARDS were age
more than 65 years, diabetes mellitus, and elevated
LDH level. Other researchers have also documented
independent predictors associated with poor out-
comes, e.g. acute illness leading to death; the need for
mechanical ventilation; and ICU admission.2
The diagnosis of SARS was based on a compre-
hensive contact history and precise laboratory tests.
The World Health Organization diagnostic criteria for
SARS have a reported sensitivity of 26% and specificity
of 96%,14 whereas the sensitivity of laboratory testing
for SARS-CoV is less than 80%.15 Since contact history
has not been reliable after SARS cluster cases were
noted in some community groups, one needed to be
highly suspicious of any transmission of pneumonia.
Our inclusion criteria added a component of trans-
mission of pneumonia, and a high degree of clinical
diagnostic accuracy was confirmed by laboratory tests.
Hematologic abnormalities, especially lympho-
penia, were common in our cohort, probably because
of ribavirin therapy. Intravenous immunoglobulin was
given when more severe hematologic abnormalities
occurred. Pancytopenia and hemophagocytosis were
noted in 2 patients without ARDS. This pheno-
menon has been noted in other viral infections, and
the outcome was fair after supportive treatment.16,17 In
our cohort, elevation of AST was more obvious than
that of ALT in the ARDS group. Since carriers of
hepatitis B virus did not show profound lung injury,
whether SARS-CoV will interact with hepatitis B virus
is not yet clear.
The location of pulmonary infiltration in SARS
patients has been reported to be the peripheral
lungs.18,19 In our cohort, initial infiltrative lesions were
mainly located in the central and peripheral lungs. The
best explanation for this is that anterior and posterior
peripheral lesions would be projected to a central
location on posteroanterior chest radiograph. The ef-
ficacy of treatment was difficult to evaluate because
patients usually received a combination of medications,
including antiviral, broad-spectrum antibacterial and
corticosteroid drugs, in addition to supportive therapy.
Initially, because the cause of SARS was thought to
be an atypical pathogen, 55 patients (82.1%) received
empiric antibacterial therapy with a fluoroquinolone.
Levofloxacin was the drug of choice in 49 patients
(73.1%) because of its broad-spectrum activity against
anaerobic and aerobic Gram-positive and Gram-
negative bacteria. In patients who developed ARDS,
stronger antibiotics such as fourth-generation
cephalosporins, teicoplanin and carbapenems were
more often used. There is no proven effective treatment
for SARS; hence, there was no difference in the
proportion of patients per group who received the
antiviral ribavirin, intravenous immunoglobulin, or
moderate amounts of corticosteroids. However, pulse
corticosteroid therapy was more often used for ARDS
than non-ARDS patients.
Our study has several limitations. It was retrospec-
tive and had no standard medical chart for following
clinical courses. Some important information may,
therefore, have been lost, which may have led to bias
in the comparison. To date, however, this is the largest
clinical analysis of SARS in Taiwan.
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